StockBox spoke to Jack Kelly (CFO) and Dave Broadbank (MD, Wind Energy Services) of European Green Transition, where they discussed strong progress in the company’s wind energy services division following
European Green Transition plc (AIM: EGT) Q1 2026 Operational Update
European Green Transition plc (AIM: EGT), a company operating in the critical infrastructure sector, provides an operational update on its Wind Energy Services business for the three months ended 31
Roaring Waters Capital builds new 9.3% stake in European Green Transition
Roaring Waters Capital, based in Dublin, has disclosed a new major holding in European Green Transition plc (AIM: EGT) following an acquisition of voting rights on 31 March 2026.
European Green Transition plc (AIM: EGT) Result of General Meeting
European Green Transition plc (AIM: EGT), a company focused on acquiring, integrating and optimising revenue-generating and profitable services businesses in the critical infrastructure sector, announces that, further to its circular
European Green Transition plc (AIM: EGT) UK proposals to increase onshore wind capacity
UK government proposals to increase onshore wind capacity
N4 Pharma changes name to Thalia Therapeutics
N4 Pharma PLC (AIM: N4P) has officially changed its name to Thalia Therapeutics plc, effective March 18, 2026.
European Green Transition plc (AIM: EGT) Result of fundraise via placing and subscription
European Green Transition plc (AIM: EGT), a company focused on acquiring, integrating and optimising revenue-generating and profitable services businesses in the critical infrastructure sector, announces that, further to its announcement
European Green Transition plc (AIM: EGT) Acquisition of infrastructure services platform
EGT has shared some very exciting news this morning as we have signed a binding share purchase agreement to acquire an established EBITDA profitable onshore wind turbine operating, maintenance, repairing
N4 Pharma plc (AIM: N4P) CEO Appointment & Name Change Thalia Therapeutics
CEO Appointment, Strategic Update and Name Change to Thalia Therapeutics
City Brokers See Potential Turning Point for hVIVO
hVIVO PLC reported annual revenue of £46.7 million, which met market expectations, prompting City brokers to evaluate whether the clinical research organisation has begun to reverse its fortunes after a
hVIVO plc (AIM: HVO) Trading Update
FY25 revenue in line and positive adjusted EBITDA Positioned to return to growth in 2026
hVIVO plc (AIM: HVO) Notice of Trading Update
Notice of Trading Update